HealthDay on MSN2d
Adjuvant Pembrolizumab Improves Survival in Muscle-Invasive Urothelial Cancer
Disease-free survival is significantly longer with adjuvant pembrolizumab than observation among patients with high-risk ...
Medpage Today on MSN6d
Survival Win for Pembrolizumab in Early Triple-Negative Breast Cancer
PD-1 inhibition before and after surgery for high-risk early triple-negative breast cancer (TNBC) led to significant ...
Medscape3d
Pembrolizumab Approved With Chemotherapy for Malignant Pleural Mesothelioma
Pembrolizumab (Keytruda, Merck) has picked up another indication — this time for the first-line treatment of unresectable ...
Merck's Keytruda Secures First FDA-Approval For Rare Form Aggressive Cancer
The FDA has approved Merck's Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for first-line ...
oncnursingnews6d
Perioperative Pembrolizumab Improves Survival in Early-Stage TNBC
Patients with early-stage triple-negative breast cancer tended to have improved survival with neoadjuvant pembrolizumab plus ...
Medscape5d
Pembrolizumab Plus Chemoradiotherapy Provides Significant Survival Benefit in Cervical Cancer
Patients with locally advanced cervical cancer were randomized to receive either pembrolizumab or placebo in combination with ...
oncnursingnews7d
Pembrolizumab Plus Chemoradiotherapy May Be New Standard in Locally Advanced Cervical Cancer
Pembrolizumab plus chemoradiotherapy improved survival in patients with previously untreated, high-risk locally advanced ...
Merck Receives Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab) Regimens as Treatment for Patients With Two Types of Gynecologic Cancers
Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced ...
emjreviews.com7d
Pembrolizumab with Chemoradiotherapy Improves Cervical Cancer Survival: ESMO 2024
Discover the results from the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study, presented at ESMO 2024, Barcelona, Spain ...
MedPage Today on MSN7d
Another Possible Treatment Option for Intermediate-Stage Liver Cancer
Median PFS increased from 10 months with TACE to 14.6 months with the addition of lenvatinib (Lenvima) and pembrolizumab ...
The New England Journal of Medicine9d
Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma
Whether pembrolizumab as adjuvant therapy would be effective in patients with high-risk muscle-invasive urothelial carcinoma after radical surgery is unknown. In this phase 3 trial, we randomly ...